Drug Patents owned by Sentynl Theraps Inc
1. List of Nulibry drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7504095 | SENTYNL THERAPS INC | Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency |
Jan, 2025
(1 year, 10 months from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Feb 26, 2028 |
| New Chemical Entity Exclusivity (NCE) | Feb 26, 2026 |
| M (M) | Oct 27, 2025 |
Drugs and Companies using FOSDENOPTERIN HYDROBROMIDE ingredient
NCE-1 date: 2025-02-26
Market Authorisation Date: 26 February, 2021
Treatment: Method of treating molybdenum cofactor deficiency type a
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
NULIBRY family patents
3
Germany
1
Portugal
1
Slovenia
1
Poland
1
United States
1
Denmark
1
Spain
1
Canada
1
Cyprus
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic